Renaissance Technologies LLC Has $3.17 Million Stock Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Renaissance Technologies LLC cut its holdings in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 26.0% during the first quarter, HoldingsChannel.com reports. The firm owned 2,299,499 shares of the company’s stock after selling 805,905 shares during the quarter. Renaissance Technologies LLC’s holdings in Autolus Therapeutics were worth $3,173,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Mak Capital One LLC raised its stake in shares of Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after buying an additional 3,987,727 shares during the last quarter. Armistice Capital LLC boosted its stake in Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,900,000 shares during the last quarter. Schroder Investment Management Group grew its holdings in Autolus Therapeutics by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock worth $18,694,000 after acquiring an additional 1,056,092 shares during the period. Bank of America Corp DE grew its holdings in Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after acquiring an additional 1,054,458 shares during the period. Finally, Cetera Investment Advisers raised its position in shares of Autolus Therapeutics by 2.7% during the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after acquiring an additional 29,324 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Wall Street Analyst Weigh In

AUTL has been the topic of several recent research reports. Wall Street Zen upgraded Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Finally, Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.75.

Autolus Therapeutics Stock Performance

AUTL opened at $2.11 on Friday. The firm’s fifty day moving average is $1.59 and its two-hundred day moving average is $1.54. The firm has a market cap of $561.59 million, a PE ratio of -1.94 and a beta of 2.07. Autolus Therapeutics PLC Sponsored ADR has a twelve month low of $1.17 and a twelve month high of $2.52.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The company had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. Equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.86 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.